Design Principles and Clinician Preferences for Pharmacogenomic Clinical Decision Support Alerts
Timothy M. Herr, Therese A. Nelson, and Justin B. Starren

TL;DR
This study explores clinician preferences for pharmacogenomic decision support alerts, emphasizing design principles like clarity, brevity, and trusted sources to enhance usability and patient care.
Contribution
It provides empirical insights into clinician preferences for PGx CDS alert design, informing future development of more effective and user-friendly tools.
Findings
Clinicians prefer interruptive pop-up alerts during order entry.
They favor brief descriptions of drug-gene interactions and clear recommendations.
Clinicians trust professional society guidelines and resources like UpToDate.
Abstract
OBJECTIVE: To better understand clinician needs and preferences for the display of pharmacogenomic (PGx) information in clinical decision support (CDS) tools. MATERIALS AND METHODS: We developed a semi-structured interview to collect feedback and preferences in six key areas of PGx CDS design, from clinicians who had prior experience with live PGx CDS tools. Eight clinicians from Northwestern Medicine's (NM) General Internal Medicine clinic participated in the study. RESULTS: Clinicians expressed preference for interruptive pop-up alerts during order entry, brief descriptions of relevant drug-gene interactions, and a clear and specific recommended alternative course of action when a medication is contraindicated. They did not wish to see detailed genetic data, preferring phenotypic information predicted from the genotype. Nor did they wish to be interrupted when genetic test results…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsEthics in Clinical Research · Pharmacogenetics and Drug Metabolism · Pharmaceutical Practices and Patient Outcomes
